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Phase IIResults: Eighty-seven patients (n Z 43 in the patritumab group; n Z 44 in placebo group)
enrolled. A median (range) of 6.5 (1e24) patritumab cycles were completed. Median PFS was
similar between the patritumab group and placebo group in the ITT population (5.6 versus 5.
5 months; hazard ratio [HR] 0.99 [95% confidence interval [CI], 0.6e1.7]; P Z 0.96) and
HRG-high subgroup (n Z 51; 5.6 versus 5.6 months; HR 0.93 [95% CI, 0.5e1.8]; P Z 0.82).
Median overall survival in the ITT population was also similar (10.0 versus 12.7 months; HR
1.3 [95% CI, 0.69e2.29]; P Z 0.46). All patients experienced 1 treatment-emergent adverse
event (TEAE). Grade III TEAEs were more frequent in the patritumab than the placebo
group (84.1% versus 60.5%). The most common grade III patritumab-related TEAE in the
patritumab group (20.5% overall) was rash (6.8%).
Conclusion: Patritumab þ cetuximab þ platinum was tolerable but not superior to
cetuximab þ platinum.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over 90% of cancers of the head and neck are squamous
cell cancers, with approximately 600,000 cases diag-
nosed worldwide each year [1,2]. Patients typically pre-
sent with advanced disease and standard-of-care is
concomitant locoregional treatment and chemotherapy
[3]. However, the recurrence rate in locally advanced
disease is approximately 50% [4].
The EXTREME regimen (non-nasopharyngeal) or
cisplatin and gemcitabine (nasopharyngeal) are recom-
mended by the National Comprehensive Cancer Care
Network (NCCN) guidelines as category 1 first-line
combination treatment for recurrent and/or metastatic
(R/M) of squamous cell carcinoma of the head and neck
(SCCHN) [5]. There is currently no category 1 single-
agent therapy for first-line treatment, though second-
line single-agent treatment with programmed cell death
protein 1 inhibitors nivolumab (category 1) or pem-
brolizumab (category 2a) are recommended for non-
nasopharyngeal R/M SCCHN. The EXTREME
regimen consists of a platinum agent (cisplatin or car-
boplatin) plus 5-fluorouracil chemotherapy and the
epidermal growth factor receptor (EGFR) inhibitor
cetuximab, which has been shown to enhance the anti-
tumour activity of platinum-based chemotherapy [6].
Patients who initially respond to cetuximab-based
therapy may later develop resistance [7,8].
A possible mechanism of cetuximab resistance is
upregulation of HER3 expression [7]. Elevated mem-
branous HER3 expression is also strongly associated
with poor prognosis in patients with SCCHN [9]. There
is growing evidence that the presence of heregulin
(HRG), a natural ligand for HER3, determines disease
progression and patient survival in SCCHN [10,11].
Patritumab is a fully human HER3 monoclonal anti-
body that binds to the extracellular domain of HER3,
promoting receptor internalisation and
degradation, and inhibiting ligands from binding
HER3dincluding HRG [12,13]. HER3 signalling isassociated with high expression of HRG [10] and shown
to be important for tumour growth and proliferation,
including in non-small cell lung cancer [14] and SCCHN
cell lines and in animal models [15]. When combined
with EGFR inhibitors, including cetuximab and pan-
itumumab, patritumab enhanced in vitro antitumour
activity and prevented HER3 activation following anti-
EGFR treatment [12,13,15].
In preclinical studies, patritumab restored cetuximab
sensitivity in colorectal cancer, and patritumab þ cetux-
imab resulted in a stronger inhibition of proliferation and
induction of apoptosis compared with either treatment
alone in patritumab-responsive SCCHN cell lines [15,16].
A phase Ib study in R/M SCCHN (clinicaltrials.gov
identifier: NCT02350712) found the combination of
patritumab plus cetuximab with platinum therapy to be
tolerated, active in patients with R/M SCCHN and did
not appear to have a significant effect on the
pharmacokinetics (PKs) of cetuximab [17]. The phase I
study recommended an 18 mg/kg loading dose of
patritumab, followed by a 9 mg/kg maintenance dose
every 21 days.
This randomised phase II study in multiple centres
across Europe evaluated safety, efficacy and PKs of
first-line cetuximab þ cisplatin or carboplatin with
either patritumab or placebo in patients with R/M
SCCHN and known HRG expression status.2. Material and methods
2.1. Overall study design
This was a multicentre, randomised, placebo-controlled,
double-blind, phase II study of first-line treatment of
patritumab plus cetuximab with platinum-based therapy
in patients with R/M SCCHN (clinicaltrials.gov
identifier: NCT02633800). This study was conducted in
compliance with the Declaration of Helsinki, the
International Conference on Harmonisation,
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national and local regulatory requirements. The
protocol was approved by the Institutional Review
Board at each study site, and all patients provided
written informed consent before participation in this
study. Patients were stratified 2:1 by HRG status high
versus low (HRG ascertained via reverse transcriptase-
PCR from tumour RNA), then randomised 1:1 to
patritumab or placebo (Fig. 1).
2.2. Patient eligibility
2.2.1. Key inclusion criteria
Adults (age 18 years) with histologically confirmed R/
M SCCHN, documented HRG expression (archived or
fresh biopsy), measurable disease per Response Evalua-
tion Criteria in Solid Tumours (RECIST) version 1.1,
human papillomavirus (HPV) status or p16 (HPV sur-
rogate), Eastern Cooperative Oncology Group (ECOG)
performance status 0 or 1, and with adequate haemato-
logical, renal and hepatic function were eligible for in-
clusion into the study. Adequate haematologic function
was defined as having an absolute neutrophil count
1.5  109/L, platelet count 100  109/L and haemo-
globin 10 g/dL. Adequate renal function was defined as
having a calculated creatinine clearance 60 mL/min.
Adequate hepatic function was defined as having an
aspartate aminotransferase and alanine aminotransferase
2.5  upper limit of normal (ULN) (<5  ULN if liver
metastases are present), alkaline phosphatase
2.0  ULN (<5  ULN if bone or liver metastases are
present) and bilirubin 1.5  ULN. Patients had pro-
thrombin time or partial thromboplastin time
1.5  ULN. Patients had to agree to comply with the
contraception requirements as specified in the study
protocol or be of non-childbearing potential.
2.2.2. Exclusion criteria
Patients were excluded if they had a prior EGFR-
targeted regimen, anti-HER3 therapy, chemotherapy
for R/M disease, anticancer therapy between biopsy andFig. 1. Study design. HRG, heregulin; PFS, progression-free survival.
multiple biopsies were not collected.submission of sample, platinum-containing drug ther-
apy with radiotherapy <6 months before the study, or
therapeutic or palliative radiation therapy or major
surgery 4 weeks before the study. Other exclusion
criteria included left ventricular ejection fraction <50%,
squamous cell tumours of the nasopharynx or a known
history of active brain metastases.
2.3. Treatment
All patients received intravenous patritumab (18 mg/kg
loading dose; 9 mg/kg maintenance dose every 3 weeks
[q3w]) or placebo, cetuximab (400 mg/m2 loading dose;
250 mg/m2 maintenance dose weekly) and up to 6 cycles
of cisplatin (100 mg/m2 q3w) or carboplatin (area under
the concentration curve [AUC] of 5) using the Calvert
formula for optimal dosing based on renal function [18].
A patient could withdraw from study treatment or
from the study at any time at their discretion. Reasons
for discontinuation from the study included progressive
disease (PD) per RECIST version 1.1 or clinician’s
assessment, adverse event (AE), withdrawal of consent,
death, protocol violation or sponsor decision to terminate
the study.
2.4. Study end-points
The co-primary efficacy end-points were to evaluate
progression-free survival (PFS) in the intent-to-treat
(ITT) and HRG-high expression populations from pa-
tients treated with patritumab þ cetuximab þ plati-
numebased therapy compared with placebo þ
cetuximab þ platinumebased therapy. Secondary effi-
cacy end-points included overall survival (OS), overall
response rate (ORR) and safety and tolerability. Safety
and tolerability end-points included treatment-emergent
adverse events (TEAEs), grade III TEAEs and serious
AEs (SAEs). PK end-points included AUC from time
0 to last measurable concentration (AUC0-last) and
maximum concentration (Cmax) for loading doses of
patritumab and cetuximab. End-points also included theaHRG status was determined at one timepoint only (at screening);
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the incidence of human antihuman antibodies (HAHA).
Analyses of treatment outcomes by tumour subsite were
not prespecified and thus not carried out.
2.5. Study assessments
PFS was defined as the time from the treatment start
date to the date of the first radiographic disease pro-
gression or death due to any cause. OS was defined as
the time from treatment start date to death from any
cause. Tumour response (complete response, partial
response, stable disease, PD) was assessed via RECIST,
version 1.1.
TEAEs were assessed per Common Terminology
Criteria for Adverse Events, version 4.03, and the
Medical Dictionary for Regulatory Activities, version
17.0. An SAE was defined as any untoward medical
occurrence that results in death, is life threatening, re-
sults in hospitalisation or prolongs existing hospital-
isation, results in a disability, is a congenital anomaly or
birth defect, or is an important medical event. Patients
who discontinued the study for any reason were fol-
lowed for 40 days after their last dose to assess the
presence of HAHA and other TEAEs. Any patients who
were positive for neutralising antibodies required
follow-up testing every 3 months for up to 1 year
following the last dose and until titres returned to
baseline or until the start of another cancer therapy.
Patient-reported outcomes were assessed using the
10-item Functional Assessment Cancer Therapy
(FACT) Head and Neck Questionnaire (FACT
H&N)da multidimensional, self-report quality of life
(QoL) instrument specifically designed for use with pa-
tients with head and neck cancerdand the 5-level
EuroQol-5-dimensions (EQ-5D-5L) instrument. In the
FACT H&N, patient well-being is assessed in four do-
mains: functional, emotional, social and physical. Each
item is rated on a 0 to 4 Likert-type scale and then
combined to produce subscale scores for each domain,
as well as a global QoL score. Higher scores represent
better QoL. The EQ-5D-5L consists of the EQ-5D-5L
descriptive system and the EuroQoL Visual Analogue
scale (EQ VAS). The EQ-5D-5L descriptive system is a
preference-based measure of health status comprising
five domains: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each domain has
five levels ranging from 1 (no problems) to 5 (extreme
problems). The EQ VAS records the respondent’s self-
rated health on a 20-cm vertical VAS with end-points
labelled ‘the best health you can imagine’ and ‘the worst
health you can imagine.’
2.6. Statistical considerations and analysis
A stratified log-rank test was performed to compare
treatment groups for PFS. A stratified Cox proportionalhazards model was used to calculate hazard ratios
(HRs) and confidence intervals (CIs). Unstratified tests
and models were used for HRG and HPV strata. PFS
was tested in the ITT analysis set and the HRG-high
stratum of the full analysis data set at a 1-sided 0.10
significance level.
Serum drug concentrations and PK parameters were
summarised using descriptive statistics, and safety data
were analysed descriptively. FACT H&N was evaluated
using mixed longitudinal modelling with treatment,
time and treatment-by-time interactions as fixed effects,
patient as random effect and baseline score as covariate.
Least square (LS) mean differences between the control
group and patritumab group are presented along with
95% CIs.
Descriptive statistics for the actual value and change
from baseline were computed for the EQ-5D-5L and EQ-
5DVASby scheduled timeof evaluation (including endof
treatment visit) for all patients and by treatment group.
Final analyses occurred after study closure with
mature OS data (i.e. when all patients had died or 13
months after the last patient was randomised; whichever
came first). After discontinuation from study treatment,
follow-up information for survival was obtained per
telephone approximately every 3months for13months.
A quantitative real-time polymerase chain reaction
(RT-PCR) assay was designed and validated (Molec-
ularMD, Portland, Oregon; data unpublished) to
quantitate HRG expression in commercial SCCHN tis-
sue samples. This validated assay was then used to
measure HRG mRNA from tumour tissue from the
patients in this study and commercial tumour tissue. The
cut-off for HRG high versus HRG low before patient
randomisation was set using the median HRG value
from commercial samples. An initial cut-off of 0.93
(delta cycle threshold [CT]) was used for randomisation
based on the commercial tumour samples in July 2015,
via quantitative RT-PCR using a 100-ng RNA input. In
July 2016, the delta CT cut-off was revised to 1.50 based
on the results of the tumour biopsy samples of the first
33 patients enrolled in this study. The median delta CT
value was chosen to determine the cut-off based on the
commercial samples and data from the study patients.3. Results
This study was conducted between December 31, 2015
(first patient enrolled) and February 21, 2018 (last pa-
tient follow-up), with the final analysis performed after
study close (database lock March 23, 2018).3.1. Patient disposition
Of the 125 patients screened, 87 enrolled and initiated
treatment (n Z 44 in the patritumab group and n Z 43
in the placebo group) (Fig. 2). All 87 patients
M.D. Forster et al. / European Journal of Cancer 123 (2019) 36e4740discontinued study treatment. The primary reason for
discontinuation was PD per RECIST version 1.1
(52.9%). Discontinuations because of TEAEs were
higher in the patritumab versus placebo group (15.9%
versus 4.7%). Overall, 44 patients (24/44 in the patritu-
mab group and 20/43 in the placebo group) died during
the study (defined as death occurring anytime during
study treatment or survival follow-up periods), with six
of those deaths (three each in the patritumab and pla-
cebo group) occurring while on treatment (defined as
death occurring on or after the first dose date to 21 days
after the last dose date of any study drug).
3.1.1. Patient demographics and baseline characteristics
In all, 87 patients (58.6% HRG high and 41.4% HRG
low) were randomised and treated. Characteristics were
similar between treatment groups (Table 1). The median
(range) age was 59.0 (33e76) years. The majority of
patients had tumour stage IV SCCHN (88.5%, nZ 77),Fig. 2. Patient disposition. EQ-5D, EuroQoL Quality of Life Scale; FA
Neck; PK, pharmacokinetics.an ECOG performance status of 1 (51.7%, n Z 45) and
had prior treatment with radiation therapy (59.8%,
n Z 52). Tumour biopsies that were used to determine
HRG RNA levels were primarily from archival (82.8%,
n Z 72 [HRG high: n Z 43; HRG low: n Z 29])
compared with fresh (17.2%, nZ 15 [HRG high: nZ 8;
HRG low: n Z 7]) specimens.
3.2. Treatment exposure
Mean (standard deviation) treatment duration was 24.2
(16.8) weeks for patritumab and 27.7 (23.3) weeks for
placebo. Mean (standard deviation) treatment duration
was similar between patritumab and placebo groups for
cetuximab (22.4 [17.0] versus 27.0 [23.7] weeks), carbo-
platin (15.2 [4.9] versus 15.0 [6.9] weeks) and cisplatin
(12.8 [7.2] versus 13.5 [7.4] weeks). Overall, a median of
6.5 (1e24) patritumab cycles were completed. In the
patritumab group (n Z 44), patients received a medianCT-H&N, Functional Assessment of Cancer TherapydHead and
Table 1
Patient demographics.
Characteristics Patritumaba
(n Z 44)
Placebob
(n Z 43)
Total
(N Z 87)
Age, years, median (range) 58.5 (35e73) 62.0 (33e76) 59.0 (33e76)
65 years, n (%) 12 (27.3) 16 (37.2) 28 (32.2)
Sex, male, n (%) 36 (81.8) 36 (83.7) 72 (82.8)
Cancer type, n (%)
Oral cavity 17 (38.6) 11 (25.6) 28 (32.2)
Oropharynx 8 (18.2) 14 (32.6) 22 (25.3)
Hypopharynx 9 (20.5) 9 (20.9) 18 (20.7)
Larynx 4 (9.1) 5 (11.6) 9 (10.3)
Other 6 (13.6) 4 (9.3) 10 (11.5)
Tumour stage at study entry, n (%)
III 3 (6.8) 3 (7.0) 6 (6.9)
IV (AeC) 40 (90.9) 37 (86.1) 77 (88.5)
Other 1 (2.3) 3 (7.0) 4 (4.6)
Prior systemic cancer
therapy, n (%)
14 (31.8) 16 (37.2) 30 (34.5)
Best response to prior therapy, n (%)
CR 9 (20.5) 10 (23.3) 19 (21.8)
PR 2 (4.5) 2 (4.7) 4 (4.6)
SD 0 1 (2.3) 1 (1.1)
PD 1 (2.3) 2 (4.7) 3 (3.4)
Unknown 2 (4.5) 1 (2.3) 3 (3.4)
Prior radiation therapy, n
(%)
25 (56.8) 27 (62.8) 52 (59.8)
Baseline ECOG performance status, n (%)
0 19 (43.2) 22 (51.2) 41 (47.1)
1 25 (56.8) 20 (46.5) 45 (51.7)
2 0 1 (2.3) 1 (1.1)
HRG expression status, n (%)
High 26 (59.1) 25 (58.1) 51 (58.6)
Low 18 (40.9) 18 (41.9) 36 (41.4)
HPV status, n (%)
Positive 8 (18.2) 8 (18.6) 16 (18.4)
Negative 36 (81.8) 35 (81.4) 71 (81.6)
Smoking status, n (%)
Current 14 (31.8) 17 (39.5) 31 (35.6)
Former 25 (56.8) 23 (53.5) 48 (55.2)
Never 4 (9.1) 3 (7.0) 7 (8.0)
Missing 1 (2.3) 0 1 (1.1)
Smoking duration, years,c
median (range)
(n Z 32)
32.5 (2e59)
(n Z 36)
39.0 (6e55)
(n Z 68)
35.9 (2e59)
Baseline 12-lead ECG, n (%)
Normal 25 (56.8) 26 (60.5) 51 (58.6)
Abnormal (NCS) 19 (43.2) 16 (37.2) 35 (40.2)
Missing 0 1 (2.3) 1 (1.1)
CR, complete response; ECG, electrocardiogram; ECOG, Eastern
Cooperative Oncology Group; HPV, human papillomavirus; HRG,
heregulin; NCS, not clinically significant; PD, progressive disease; PR,
partial response; SCCHN, squamous cell carcinoma of the head and
neck; SD, stable disease.
a Patritumab group Z patritumab þ cetuximab þ cisplatin or
carboplatin.
b Placebo groupZ placebo þ cetuximab þ cisplatin or carboplatin.
c Patients for whom data was available.
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or 5.0 (1e6) cisplatin (n Z 15) cycles. In the placebo
group (nZ 43), patients received a median of 5.0 (1e6)
cycles for both carboplatin (nZ 35) or cisplatin (nZ 9).
Two patients in the patritumab group and one in the
placebo group switched from cisplatin to carboplatin.Mean (standard deviation) cumulative doses of pat-
ritumab and placebo received per patient were 73.4
(63.0) mg/kg and 84.7 (64.3) mg/kg and the mean
(standard deviation) durations of treatment were 24.2
(16.8) weeks and 27.7 (23.3) weeks, respectively. Of the
44 patients treated with patritumab, 86.4%, 11.4% and
2.3% required 0, 1 or 2 patritumab dose reductions,
respectively.
3.3. Efficacy
3.3.1. PFS and OS
Median PFS was 5.6 (95% CI, 4.1e6.5) months for the
patritumab group and 5.5 (95% CI, 4.2e6.4) months for
the placebo group (HR 0.99 [95% CI, 0.6e1.7];
P Z 0.96) (Fig. 3A). In the HRG-high subgroup, me-
dian PFS was 5.6 (95% CI, 4.1e11.2) months for the
patritumab group and 5.6 (95% CI, 3.1e8.3) months for
the placebo group (HR 0.93 [95% CI, 0.5e1.8];
P Z 0.82) (Fig. 3B). Similarly, no differences were
observed between treatment groups in the HRG-low or
HPV-negative subgroups (Fig. 3CeD). The sample size
for the HPV-positive group (n Z 8 each in the patritu-
mab and placebo groups) was too small to offer mean-
ingful interpretation.
There was no statistical difference in OS between
treatment groups in the ITT population or in the HRG
subgroup (Fig. 4AeC); median OS was non-evaluable in
the HPV subgroups. For the ITT population, median
OS was 10.0 months in the patritumab group and 12.7
months in the placebo group (HR 1.26 [95% CI,
0.69e2.29]; P Z 0.46).
3.3.2. Tumour response
The ORR for all patients was 36.4% in the patritumab
group and 27.9% in the placebo group (Supplementary
Table S1). Response rates were similar between treat-
ment groups, regardless of HRG or HPV status. Best
(minimum) percent change in sum of diameters from
baseline in target lesions per patient is illustrated in
Fig. 5. The mean (standard deviation) best (minimum)
percent change in sum of longest diameters (mm) from
baseline in target lesion (mm) in the patritumab and
placebo groups, respectively, were 32.2% (31.3%) and
19.1% (36.3%) in the ITT population and 32.0% (32.6%)
and 22.5% (32.7%) in the HRG-high subgroup.
3.4. Safety
3.4.1. TEAEs and SAEs
All patients experienced at least one TEAE (Table 2).
TEAEs grade III were more frequent in the patritu-
mab group than in the placebo group (84.1% versus
60.5%). The proportion of all patients with TEAEs
grade III was similar between the HRG-high (36/51,
70.6%) and HRG-low (27/36, 75.0%) groups. TEAEs
considered related to patritumab/placebo were reported
Fig. 4. Overall survival. A, ITT. B, HRG high. C, HRG low. HPV
subgroups were non-evaluable for OS; median (95% CI) OS with
patritumab versus placebo was: NE (4.1eNE) vs. 5.6 (2.7e8.2) in
the HPV-positive subgroup and 9.3 (5.4e13.3) vs NE (9.0-NE) in
the HPV-negative subgroup. aPatritumab
group Z patritumab þ cetuximab þ cisplatin or carboplatin;
bPlacebo group Z placebo þ cetuximab þ cisplatin or carbopla-
tin. CI, confidence interval; HPV, human papillomavirus; HRG,
heregulin; ITT, intent-to-treat; NE, non-evaluable; OS, overall
survival.
Fig. 3. Progression-free survival. A, ITT. B, HRG high. C, HRG
low. D, HPV-negative. aPatritumab
group Z patritumab þ cetuximab þ cisplatin or carboplatin;
bPlacebo group Z placebo þ cetuximab þ cisplatin or carbopla-
tin. CI, confidence interval; HPV, human papillomavirus; HRG,
heregulin; ITT, intent-to-treat; PFS, progression-free survival.
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and 37.2% (n Z 16) of patients in the placebo group.
Grade III TEAEs considered related to patritumab in
the patritumab group were reported in 20.5% (nZ 9) of
patients and included rash (6.8%, n Z 3), anaemia
(4.5%, n Z 2), neutropenia (4.5%, n Z 2), acne (2.3%,
n Z 1), dermatitis acneiform (2.3%, n Z 1), ejection
fraction decreased (2.3%, n Z 1), empyema (2.3%,
n Z 1), hypomagnesemia (2.3%, n Z 1), melena (2.3%,
Fig. 5. Best (minimum) percent change in sum of diameters from baseline in target lesions. Dotted line represents response (30) and
disease progression (þ20). CR, complete response; ITT, intent-to-treat; NE, non-evaluable; PD, progressive disease; PR, partial response;
SD, stable disease.
Table 2
Treatment-emergent adverse events.
TEAE Number of patients with a TEAE, n (%)
Patritumaba (n Z 44) Placebob (n Z 43)
All grades Grade III All grades Grade III
Any TEAE 44 (100) 37 (84.1) 43 (100) 26 (60.5)
TEAE, by preferred term
Rash 20 (45.5) 6 (13.6) 21 (48.8) 0
Anaemia 18 (40.9) 5 (11.4) 12 (27.9) 6 (14.0)
Hypomagnesemia 16 (36.4) 2 (4.5) 15 (34.9) 1 (2.3)
Nausea 16 (36.4) 0 14 (32.6) 2 (4.7)
Acneiform dermatitis 15 (34.1) 6 (13.6) 8 (18.6) 3 (7.0)
Paronychia 15 (34.1) 3 (6.8) 4 (9.3) 0
Neutropenia 13 (29.5) 5 (11.4) 11 (25.6) 4 (9.3)
Diarrhoea 12 (27.3) 0 6 (14.0) 1 (2.3)
Hypokalaemia 12 (27.3) 3 (6.8) 2 (4.7) 0
Weight decreased 12 (27.3) 0 10 (23.3) 0
Decreased appetite 11 (25.0) 1 (2.3) 11 (25.6) 3 (7.0)
Fatigue 11 (25.0) 0 7 (16.3) 1 (2.3)
Thrombocytopaenia 10 (22.7) 0 14 (32.6) 4 (9.3)
Asthenia 9 (20.5) 0 11 (25.6) 3 (7.0)
Dysphagia 9 (20.5) 5 (11.4) 4 (9.3) 1 (2.3)
Vomiting 9 (20.5) 0 7 (16.3) 0
Mucosal inflammation 8 (18.2) 1 (2.3) 2 (4.7) 0
Dyspnoea 7 (15.9) 4 (9.1) 5 (11.6) 1 (2.3)
Skin fissures 7 (15.9) 1 (2.3) 6 (14.0) 0
Conjunctivitis 6 (13.6) 0 4 (9.3) 0
Constipation 6 (13.6) 0 4 (9.3) 0
Dry skin 6 (13.6) 1 (2.3) 7 (16.3) 0
Cough 5 (11.4) 0 5 (11.6) 0
Leucocytosis 5 (11.4) 0 0 0
Stomatitis 5 (11.4) 1 (2.3) 3 (7.0) 0
Headache 3 (6.8) 0 5 (11.6) 1 (2.3)
Folliculitis 2 (4.5) 0 5 (11.6) 0
Hypophosphataemia 2 (4.5) 0 5 (11.6) 4 (9.3)
TEAE, treatment emergent adverse event.
a Patritumab group Z patritumab þ cetuximab þ cisplatin or carboplatin.
b Placebo group Z placebo þ cetuximab þ cisplatin or carboplatin.
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(2.3%, n Z 1), rash pustular (2.3%, n Z 1) and stoma-
titis (2.3%, n Z 1).SAEs were reported in 43.2% and 37.2% of patients
in the patritumab and placebo groups, respectively
(Table 3 and Supplementary Table S2). The proportion
Table 3
SAEs in 2 patients.
SAE Number of patients with an SAE, n (%)
Patritumaba (n Z 44) Placebob (n Z 43)
All grades Grade III All grades Grade III
Any treatment emergent SAE 19 (43.2) 19 (43.2) 16 (37.2) 14 (32.6)
Treatment emergent SAE, by preferred term (in 2 patients)
Dehydration 3 (6.8) 2 (4.5) 2 (4.7) 2 (4.7)
Pneumonia 4 (9.1) 3 (6.8) 0 0
Tumour haemorrhage 0 0 4 (9.3) 3 (7.0)
Device-related infection 2 (4.5) 2 (4.5) 0 0
Sepsis 0 0 2 (4.7) 1 (2.3)
Cardiovascular insufficiency 1 (2.3) 1 (2.3) 1 (2.3) 1 (2.3)
SAE, serious adverse event.
a Patritumab group Z patritumab þ cetuximab þ cisplatin or carboplatin.
b Placebo group Z placebo þ cetuximab þ cisplatin or carboplatin.
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in the HRG-high and 50.0% (18/36) in the HRG-low
group. SAEs were considered related to patritumab in
6.8% (n Z 3) of patients in the patritumab group and
7.0% (n Z 3) in the placebo group. Patritumab dose
reduction was reported in six (13.6%) patients, consid-
ered related to patritumab in four (9.1%) patients.
Treatment-emergent SAEs leading to death occurred in
five (11.4%) patients in the patritumab group and seven
(16.3%) patients in the placebo group. In the patritumab
group, one (2.3%) death due to cardiovascular insuffi-
ciency was considered related to cetuximab. In the pla-
cebo group, one (2.3%) death due to hypoxia was
considered related to patritumab/placebo by the inves-
tigator, but the investigator was blinded to the treatment
group. No other deaths were considered related to
treatment.
3.4.2. Development of HAHAs
In all, five patients (n Z 3 HRG high and n Z 2 HRG
low) had 1 HAHA-positive titre over the course of the
study. One patient had a transient positive titre (1:40)
which was negative at study end, and four patients had a
positive titre. Of the four patients with a positive titre at
study end, two had a 1:<10 titre, one had a 1:20 titre
and one had a 1:80 titre.
3.5. Pharmacokinetics
The PK analysis set included 11 patients in the patri-
tumab group and seven patients in the placebo group.
At 7 h post-infusion, mean (standard deviation) patri-
tumab concentration was 318.5 (85.7) mg/mL, decreasing
to 242.6 (65.0) mg/mL, 183.2 (88.9) mg/mL, 91.2 (39.8)
mg/mL and 43.5 (18.5) mg/mL at 24, 48, 168 and 336 h
post-infusion, respectively; by 504 h, patritumab con-
centration had decreased to 54.0 (83.7) mg/mL
(Supplementary Fig. S1A).
In the patritumab group, mean (standard deviation)
cetuximab concentration was 169.3 (57.5) mg/mL at the
end of the first infusion, increasing to 196.5 (42.1) mg/mL at 4 h post-infusion and then decreasing to 127.7
(24.1) mg/mL, 95.7 (35.8) mg/mL and 34.9 (13.0) mg/mL
at 24, 48 and 168 h post-infusion, respectively
(Supplementary Fig. S1B). In the placebo group, mean
(standard deviation) cetuximab concentration was 117.7
(48.1) mg/mL at the end of the first infusion, increasing
to 167.4 (80.4) mg/mL at 4 h post-infusion and then
decreasing to 109.0 (47.3) mg/mL, 81.0 (40.0) mg/mL and
35.1 (21.0) mg/mL at 24, 48 and 168 h post-infusion,
respectively (Supplementary Fig. S1B).
3.6. Patient-reported outcomes
3.6.1. FACT H&N
Mean (standard deviation) FACT H&N total scores,
which measure overall QoL for patients with head and
neck cancers, at baseline were similar between the pat-
ritumab (97.0 [23.4]) group and the placebo (100 [25.4])
group. At day 1 cycle 15, the LS mean difference from
baseline was similar between the patritumab (2.1 [95%
CI, 13.5, 9.2]) and placebo (1.8 [95% CI, 12.0, 8.5])
groups (LS mean difference: 0.4 [95% CI, 15.7, 15.0]
(Supplementary Table S3). Similar results were reported
for the following subscales: functional well-being, which
assessed patient-perceived ability to function success-
fully in daily life (LS mean difference: 0.7 [95% CI,
4.4, 4.2]), emotional well-being, which assessed pa-
tients’ level of anxiety and fear surrounding their illness
(LS mean difference: 1.1 [95% CI, 4.5, 2.3]), social
well-being, which assessed patient satisfaction with the
support they receive from friends and family (LS mean
difference: 0.2; 95% CI, 3.9, 3.5) and physical well-
being, which assessed patient satisfaction with their en-
ergy level and mobility (LS mean difference: 1.1 [95%
CI, 5.1, 2.9]).
3.6.2. EQ-5D-5L
The mean (standard deviation) of EQ-5D-5L
(measuring patient satisfaction with mobility, self-care,
usual activities, pain/discomfort and anxiety/depression)
scores at baseline were similar between patritumab (0.7
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at the last observation for both patritumab (0.7 [0.3])
and placebo (0.7 [0.3]) groups. For EQ VAS, mean
(standard deviation) VAS score at baseline was 67.4
(21.4) in the patritumab group and 72.1 (15.1) in the
placebo group. At last observation on treatment, mean
(standard deviation) VAS score decreased, indicating a
perceived decrease in overall health, to 64.1 (19.6) in the
patritumab group and 69.4 (16.3) in the placebo group.4. Discussion
Data from this phase II, randomised, placebo-controlled
study showed that patritumab, cetuximab and platinum
were not superior to cetuximab and platinum therapy
for the treatment of R/M SCCHN. Current NCCN
guidelines recommend cetuximab as treatment for R/M
SCCHN [5]. In a phase III study of 117 patients with R/
M SCCHN, the addition of cetuximab to cisplatin
treatment showed increased clinical activity compared
with cisplatin alone, though no differences in PFS or OS
were observed [19]. Further, cetuximab response is
limited; up to 36% of patients respond to the
EXTREME regimen and 13% of patients respond to
cetuximab monotherapy [6,20]. Many patients who
initially respond develop resistance, which may be
because of an overexpression of HRG [6,21]. High HRG
expression has also been shown to correlate with
reduced PFS and OS in SCCHN [10,11]. As this phase
Ib study demonstrated activity of patritumab plus
cetuximab with platinum-based therapy in patients with
R/M SCCHN [17], the clinical relevance of HRG as a
biomarker in SCCHN was evaluated in this study.
In the current study, compared with
cetuximab plus platinum therapy, combination treat-
ment with patritumab did not improve PFS or OS in the
ITT population or in the HRG-high subgroup. HRG
expression, therefore, does not appear to be a useful
predictive biomarker of benefit from patritumab.
Interestingly, patients who were HPV-positive had
slightly but not significantly, better OS (non-evaluable
versus 5.6 months) and PFS (6.5 versus 2.7 months)
results in the patritumab group compared with the
placebo group, though the number of patients in this
subgroup were too small to detect a clinically mean-
ingful difference.
Overall, treatment with patritumab in combination
with cetuximab and cisplatin or carboplatin in the cur-
rent study was tolerable. Patritumab-related TEAEs
were reported in 52.3% of patients in the patritumab
group. Notably, patritumab-related TEAEs were also
reported in 37.2% of patients in the placebo group,
though misattribution of TEAEs is not uncommon. A
study investigating 398 patients across two phase III
trials found that approximately 50% of TEAEs reported
in the placebo groups were attributed to the study drug[22]. TEAEs grade III were more frequently reported
in the patritumab versus the placebo group (84.1%
versus 60.5%). However, the proportion of patients
reporting SAEs were similar between groups (43.2%
versus 37.2%). Six patients had a dose reduction, four of
which were because of a patritumab-related TEAE.
Interestingly, a higher proportion of patients in the
HRG-low subgroup had TEAEs grade III compared
with the HRG-high subgroup (50.0% versus 29.4%). The
PK profiles in this study were similar to those reported
in the phase I study of patritumab þ cetuximab þ
platinum chemotherapy [17]. In both the placebo and
patritumab groups, cetuximab concentration increased
in the first 6 h post-dosing before steadily declining,
indicating that patritumab had a minimal effect on
cetuximab PK. Patient QoL was assessed using both the
FACT-H&N and EQ-5D-5L. Results showed that
showed that QoL remained stable over the course of the
study and was similar for both the patritumab and
placebo groups.
While the cetuximab þ platinum chemotherapy has
been the standard of care of R/M SCCHN, the treat-
ment landscape is changing. The phase III KEYNOTE-
048 study found that first-line treatment with pem-
brolizumab, a PD-L1 inhibitor, improved OS compared
with the EXTREME regimen in patients with R/M
SCCHN whose tumours expressed PD-L1 with a com-
bined positive score 20 (14.9 months versus 10.7
months; P Z 0.0007) and combined positive score 1
(12.3 months versus 10.3 months, P Z 0.0086) [23].
Combination treatment with pembrolizumab and
chemotherapy also improved OS compared with the
EXTREME regimen in the overall patient population
(13.0 months versus 10.7 months; P Z 0.0034). In the
current study, though patritumab did not improve OS
with cetuximab and platinum therapy, patritumab was
tolerable. Given these data, it is hypothesised that the
resistance mechanism for cetuximab in SCCHN may not
only be driven by HER3, but also by other not-yet-
defined pathways (e.g. tyrosine kinase receptors and
other cellular receptors) that may be mediating resis-
tance. U3-1402, a first-in-class HER3-targeting antidrug
conjugate composed of patritumab covalently conju-
gated to a drug-linker (MAAA-1162a) containing a drug
component (MAAA-1181a), is currently in phase I/II
trials for the treatment of HER3-expressing breast
cancer (clinicaltrials.gov identifier: NCT02980341) [24].
4.1. Limitations
A low number of patients in subgroups may have
limited the ability to assess efficacy in HRG and HPV
subgroups. In the majority of patients, archived tumour
tissue was used to determine HRG status, and there may
exist some temporal heterogeneity in HRG levels. As
paired analysis from fresh and archived tumour tissue
was not done, it cannot be ruled out that patients with
M.D. Forster et al. / European Journal of Cancer 123 (2019) 36e4746HRG-high statusdas ascertained from archival tumour
biopsiesdmay in fact be of HRG-low status from fresh
tumour biopsies (and vice versa). However, to the
knowledge of the authors, no published literature in
SCCHN demonstrates that HRG levels change over
time. Further, there was good representation of HRG-
high and HRG-low status in both archived and fresh
tumour tissue in the current study.
5. Conclusions
The combination of patritumab with cetuximab and
platinum therapy was tolerable but was not more effi-
cacious compared with cetuximab and platinum ther-
apy. This study will not continue into a phase III clinical
trial.
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